When and How to prescribe DPP-IV inhibitor & SGLT2 inhibitor combination ? скачать в хорошем качестве

When and How to prescribe DPP-IV inhibitor & SGLT2 inhibitor combination ?

When and How to prescribe DPP-IV inhibitor & SGLT2 inhibitor combination by Dr. Om J Lakhani Video Summary: 00:13 💊 The discussion mainly focused on the prescription of SGLT2 inhibitor in combination with DPP-IV inhibitor, available combinations, ideal patients for this medication, and its benefits. 01:20 🇮🇳 The combinations of these drugs that are commonly used in India 02:45 🩺 A typical profile of patients eligible for a DPP4 and SGLT2 combination is a 50-year-old, Type 2 diabetes patient with a history of coronary artery disease and HbA1c of 8.7%. 05:49 🔢 The combination of SGLT2 and DPP4 inhibitors reduces HbA1c by 1.5 to 1.7% when added to Metformin. 10:14 🎯 By using SGLT2 and DPP-IV inhibitors combination, multiple pathways are being targeted which contributes to the efficiency of this combination in controlling diabetes. 22:12 💓 The benefit of the SGLT2 and DPP-IV inhibitor combination also extends to cardiovascular risks, as it significantly reduces these risks. Moreover, the reduction benefit is applicable in Asian patients as well with a 56% reduction observed. 23:04 💔 EMPALINA can be prescribed across various heart failure phenotypes including patients with reduced, mid-range, and normal ejection fraction. 23:18 🩺 Both EMPA and LENA have shown reductions in urine albumin-creatinine ratio, proving their benefits in cases of chronic kidney disease. Their prescription can be safely continued till the eGFR level is down to 20. 24:00 🚫 Contraindications for this combination include pregnancy, Type 1 diabetes, patients with eGFR less than 20, and patients with a history of pancreatitis. 26:13 🎯 ADA guidelines recommend the usage of the SGLT2 inhibitor, especially in patients with prior history of atherosclerotic cardiovascular disease or at high risk. The combination therapy is also beneficial for patients with uncontrolled HbA1c levels on Metformin, treatment-naive patients, and patients with diabetic nephropathy.